AccuBioTech Empowers Chagas Disease Control: Accu-Tell® Chagas Cassette (WSP) Rapid Test Safeguards Global Health
On the occasion of the 11th World Chagas Disease Day, AccuBioTech Co., Ltd. proudly introduces the Accu-Tell® Chagas Cassette (WSP) Rapid Test—a groundbreaking solution for early diagnosis and global control of Chagas disease.
April 14 marks World Chagas Disease Day, a pivotal occasion to raise global awareness and advance prevention and treatment efforts for this neglected tropical disease. Caused by the parasite Trypanosoma cruzi, Chagas disease remains a significant public health challenge, affecting millions worldwide. According to the World Health Organization (WHO), an estimated 16–18 million people are infected globally, with approximately 50,000 annual deaths attributed to chronic complications. The disease imposes not only physical suffering on patients but also a substantial burden on public health systems.
On the occasion of the 11th World Chagas Disease Day, AccuBioTech Co., Ltd. proudly introduces the Accu-Tell® Chagas Cassette (Whole Blood/Serum/Plasma) Rapid Test—a groundbreaking solution for early diagnosis and global control of Chagas disease.
Accu-Tell® Chagas Cassette (Whole Blood/Serum/Plasma): a fast, convenient and accurate diagnostic tool
This Chagas rapid test uses lateral flow immunochromatography to qualitatively detect anti-Trypanosoma cruzi IgG antibodies in human whole blood, serum or plasma. It is easy to use, requires no complex instrumentation and produces results in 15 minutes. In terms of detection principle, the product ensures process and performance by pre-coating recombinant antigen in the detection line region of the test membrane and utilising an independent quality control system.
In terms of performance, the Accu-Tell® Chagas Cassette excels. When tested against a commercial IgG enzyme immunoassay (EIA) test on 235 samples, the relative sensitivity was 94.7%, the relative specificity was 99.1%, and the overall compliance rate was 98.7%. This fully proves the accuracy and reliability of the product, which is able to provide effective testing basis for medical workers.
Its main features include:
- Fast and convenient: simple operation, no need for complex equipment, especially suitable for on-site testing in resource-limited areas.
- High sensitivity and specificity: accurately identifies early infections and reduces missed and misdiagnosed infections.
- Global applicability: Applicable to patient groups in different endemic regions, contributing to the construction of a global Chagas disease prevention and control network.
Commitment to Global Health
At AccuBioTech, we are committed to advancing the development and innovation of in vitro diagnostic solutions. The Accu-Tell® Chagas Cassette exemplifies our dedication to addressing critical public health challenges. By enabling rapid screening and auxiliary diagnosis, this product aims to bolster Chagas disease control initiatives worldwide.
Looking ahead, we will continue to invest in research and technological advancements to enhance diagnostic capabilities, reaffirming our unwavering commitment to safeguarding human health.